SPRY Stock Analysis: Buy, Sell, or Hold?
SPRY - ARS Pharmaceuticals, Inc. Common Stock
$7.61
-0.13 (-1.68%)
▼
5d:
-7.08%
30d:
-20.65%
90d:
-4.87%
HOLD
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 12, 2026
27d
Get Alerted When SPRY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SPRY shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SPRY shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SPRY is currently trading at $7.61, which is considered oversold relative to its 30-day fair value range of $8.01 to $9.75.
Technical Outlook: Technically, SPRY is showing sideways momentum. The price is currently testing key support at $7.49. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.75 (+251.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SPRY is showing sideways momentum. The price is currently testing key support at $7.49. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.75 (+251.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.01 -
$9.75
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 251.5% below Wall St target ($26.75)
- CAUTION: Recommendation downgraded due to -7.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$8.01 -
$9.75
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.49
Resistance Level
$8.66
Current Trend
Sideways
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.07
Wall Street Target
$26.75
(+251.5%)
Revenue Growth (YoY)
184.5%
Profit Margin
-200.0%
Share & Embed Analysis
Last updated: July 14, 2026 7:45 PM ET
Data refreshes hourly during market hours. Next update: 8:45 PM
Data refreshes hourly during market hours. Next update: 8:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 52 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
